Dr. John Carl Hoefs, MD

39. Hoefs JC: Diagnostic paracentesis: a potent clinical tool. Gastroenterology 1990;98:230-236. 44. Hoefs JC: Globulin Correction of Albumin Gradient: Correlation with Measured Serum to Ascites Colloid Osmotic Pressure Gradients. Hepatology 1992;16:396-403. 45. Chang KJ, Hoefs JC: Ascites and Encephalopathy. Current Opinion in Gastroenterology 1992;8:398-402. 48. Fong TL, Morgan T, Phan C, Hoefs JC: Raising the Dose of Interferon does not Improve the Response in Chronic Hepatitis C. J Clin Gastroenterol 1995;20:42-44. 49. Hoefs JC, Chang K, Wang F, Kanel G, Morgan T, Braunstein P: The Perfused Kupffer Cell Mass: Correlation With Histology and Severity of CLD. Digestive Diseases and Sciences 1995:40(3):552-560. 50. Hoefs JC, Wang F, Kanel G, Braunstein P: The Liver-Spleen Scan as a Quantitative Liver Function Test: Correlation with Liver Severity at Peritoneoscopy. Hepatology 1995;22:1113-1121. 51. Hoefs JC, Wang F, Kanel G: Functional Measurement of the Non-Fibrotic Hepatic Mass in Cirrhotic Patients. Am J of Gastroenterol 1997;92:2054-2058. 53. Keeffe Emmet B, Hollinger B, [Hoefs, JC] and the Consensus Interferon Study Group: Therapy of Hepatitis C: Consensus Interferon Trials. Hepatology 1997;26(Suppl 1):101S-107S. Hoefs JC, Wang FW, Walker B, Kanel G. A novel, simple method of functional spleen volume calculation by liver-spleen scan. J Nuc Med. 1999;40:1745-55. 70. Hoefs JC, Sheikh M, Guererro HJ Milne N: Factors affecting the quantitative liver spleen scan in normal individuals. Digestive Diseases and Sciences 2005; 50:283-9 72. Zell J, Hoefs J, Ou S-H, Chang J, Yoon E. Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab. Anti Cancer Drugs 2005; 16:83-5 73. Hoefs JC, Chen PT, Lizotte P. Non-invasive Evaluation of Liver disease Severity. Clin of Liver Dis Dec 2006; 10: 535-562. 74. Hoefs J, Aulakh VS. Treatment of chronic HCV infection in special populations. Int J Med Sci. 2006;3 (2):69-74. 76. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology. 2006 Dec;44 (6):1675-84. 78. Hoefs JC, Morgan TR. 72 weeks of treatment for patients with partial EVR? (editorial). Hepatology 2007; 46:1671-4. 79. Everson GT, Shiffman ML, Morgan TR, Hoefs JC, Sterling RK, Wagner DA, Kugelmas M, Doherty MC, Wright EC, and the HALT-C Trial Group The Spectrum of Hepatic Functional Impairment in Patients with Fibrosis and Compensated Cirrhosis Due to Chronic Hepatitis C: Results from the HALT-C Trial. Alimentary Pharmacology & Therapeutics 2008; 27(9):798-809. 82. Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG, and the HALT-C Trial Group. Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial. Gastroenterology 2009 Dec; 137(6):1986-94. Epub 2009 Sep 10. 83. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R, HALT-C Trial Group. Coffee Intake is Associated with Lower Rates of Liver Disease Progression in Chronic Hepatitis C. Hepatology. 2009 Nov;50(5):1360-9. Comment in Hepatology. 2009 Nov;50(5):1673, author reply 1673. 84. Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, Ghany MG, Prognostic Value of Ishak Fibrosis Stage: Findings from the HALT-C Trial Hepatology. 2010 Dec;51(2):585-94 85. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Des-gamma-carboxy Prothrombin and Alpha fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma Gastroenterology 2010 Feb; 138: 493-502.